-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-01
SDGR:NSD- (USD)
COMMON STOCK | Health Information Services |
Last Closing
USD 18.84Change
-0.90 (-4.56)%Market Cap
USD 1.58BVolume
1.18MVerdict
Verdict
Values as of: 2025-04-01
COMMON STOCK | Health Information Services |
Last Closing
USD 18.84Change
-0.90 (-4.56)%Market Cap
USD 1.58BVolume
1.18MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
GEHC | GE HealthCare Technologies Inc.. |
N/A |
USD 39.59B |
TEM | Tempus AI, Inc. Class A Common.. |
N/A |
USD 9.00B |
HQY | HealthEquity Inc |
N/A |
USD 7.52B |
WAY | Waystar Holding Corp. Common S.. |
N/A |
USD 4.47B |
BTSG | BrightSpring Health Services, .. |
N/A |
USD 3.36B |
PRVA | Privia Health Group Inc |
N/A |
USD 2.89B |
PINC | Premier Inc |
N/A |
USD 1.93B |
OMCL | Omnicell Inc |
N/A |
USD 1.78B |
GDRX | Goodrx Holdings Inc |
N/A |
USD 1.73B |
CERT | Certara Inc |
N/A |
USD 1.60B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
ARKG:LSE | ARK Genomic Revolution UC.. | 4.55 % | 0.00 % |
N/A |
USD 9.33M |
ARCG:LSE | ARK Genomic Revolution UC.. | 4.43 % | 0.00 % |
N/A |
USD 9.51M |
CNCR | Loncar Cancer Immunothera.. | 2.10 % | 0.79 % |
N/A |
USD 8.35M |
ARKG | ARK Genomic Revolution ET.. | 0.00 % | 0.75 % |
N/A |
USD 1.06B |
WELL:LSE | Hanetf Icav - Han-Gins He.. | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -2.33% | 62% | D | 60% | D- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -2.33% | 62% | D | 60% | D- | ||
Trailing 12 Months | |||||||
Capital Gain | -24.88% | 60% | D- | 37% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -24.88% | 60% | D- | 36% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -50.36% | 50% | F | 23% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -50.36% | 50% | F | 22% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -15.41% | 38% | F | 17% | F | ||
Dividend Return | -15.41% | 36% | F | 17% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 41.63% | 58% | F | 44% | F | ||
Risk Adjusted Return | -37.01% | 38% | F | 18% | F | ||
Market Capitalization | 1.58B | 77% | C+ | 78% | C+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector